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Abstract 
Hidradenocarcinomas are rare, aggressive adnexal tumors of sweat gland origin that 
demonstrate a high potential for local recurrence, metastasis and poor outcome. These 
neoplasms can derive from preexisting clear cell hidradenomas, but more commonly 
appear de novo with the molecular events responsible for the pathogenesis currently 
unknown. Molecular markers of pathogenesis as well as effective forms of adjuvant 
chemotherapy are missing due to the lack of accurate diagnosis, paucity of cases and 
confusion with other visceral solid tumors. Here, we report a 37-year-old man who 
presented with a rapidly growing, painful palpable mass located in the right inguinal 
area. The patient was a nonsmoker, did not consume alcohol and had a medical history 
remarkable only for a lower abdominal superficial skin lesion in the same area that had 
been excised 11 years earlier. Although initially slow growing, the lesion eventually 
expanded, was surgically excised and was diagnosed as a hidradenoma. There was no 
family history of malignancy and the patient had not experienced any constitutional 
symptoms. We probed the immunohistochemical status and detected negative staining 
for the estrogen, progesterone and Her2 receptors, while strong, diffuse nuclear staining 
was seen in the majority of cells consistent with p53 overexpression. Similarly, strong 
nuclear reactivity was seen with p63 and p73 antibodies. The p63 gene contains 2 
separate promoters which express at least 6 major transcripts that lead to 2 
fundamentally different classes of proteins; 3 isoforms (TAp63α, β and γ) encode proteins 
that induce apoptosis, whereas the other 3 isoforms (ΔNp63α, β and γ) may exert 
inhibitory effects on p53. Interest in p63 stems from this ‘two genes in one’-concept. 
Importantly, the nuclear presence of ΔNp63 was detected widespread throughout the 
tumor. We have identified a subtype of hidradenocarcinomas that express ΔNp63 and  
Case Rep Oncol 2009;2:44–52 
DOI: 10.1159/000205351 
Published online: March 14, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
45
uncovered an unforeseen commonality with triple-negative breast tumors. To our 
knowledge, this is the first report of a sweat gland tumor that displayed expression of 
both ΔNp63 and p73 and demonstrated a triple-negative receptor status. Such a link 
between 2 seemingly disparate tumor types indicates a mutual pathway of 
tumorigenesis and suggests the potential for common therapeutic regimens. 
 
Background 
Hidradenocarcinomas are rare, intradermal malignant sweat gland tumors that present 
as asymptomatic, nondescript cutaneous lesions with a reported incidence rate of around 
0.05% in the United States [1]. Diagnosis is made primarily in the fifth to seventh decades 
of life, with similar incidence in men and women and without racial predilection. 
Historically, diagnosis has been difficult due to the paucity of cases, inconsistent 
nomenclature, variable morphology and confusion with visceral, metastatic tumors. 
Generally, lesions present on the face or extremities; however, cases have also been 
reported with lesions on the abdomen, trunk and groin and even more unusually on the 
scalp, elbow and digits. Typically the tumor appears as a ‘benign’ solitary skin lesion and 
maintains a stable size or may slowly expand. Hidradenocarcinomas exhibit a lack of 
distinguishable features and following excisional biopsy or local excision, the primary 
lesion may remain dormant or recur slowly in situ. Most patients remain asymptomatic 
without any overt effect other than pain, bleeding with contact or ulceration. At some 
point, through an unknown mechanism, the tumor assumes an aggressive clinical course 
with growth at regional or distant metastatic sites; primarily lymph nodes. Tumors 
demonstrate up to 50% local recurrence despite aggressive surgical management, and 
prognosis is generally poor with a 5-year disease-free survival rate of less than 30% [2]. 
Case Presentation 
A 37-year-old Caucasian male presented to his internist to report an enlarged, tender right inguinal 
mass that had progressively increased in size over the previous months. In addition, he noted a long-
standing, smooth, quarter-sized skin lesion on his right lower abdomen which had recently begun to 
bleed at the base upon physical contact. Eleven years earlier, the same skin lesion had been biopsied at 
an overseas medical facility and was diagnosed by gross pathology as a hidradenoma that extended to 
the surgical margins with recommendation for complete excision. Shortly after biopsy the mass 
recurred, elevated the surrounding skin and tripled in size. The lesion remained otherwise stable and the 
patient was lost to follow-up for over a decade. Upon presentation, physical examination revealed an 
otherwise healthy, age-appropriate male, without any other palpable lymphadenopathy or 
organomegaly. A complete blood count and comprehensive metabolic panel were unremarkable and a 
viral screen was negative. Subsequent to presentation, both the abdominal lesion and right inguinal 
lymph node were concurrently excised. 
Gross Pathology and Microscopic Findings 
The gross abdominal specimen measured 4.2 × 2.5 cm, was excised to a depth of 3.2 cm, 
demonstrated an elevated, ulcerated surface and was comprised of atypical, uniform polygonal cells 
suspicious for malignancy of adnexal origin (fig. 1a). At high power, residual multinodular tumor was 
observed with infiltrative growth which consisted of epithelial cells with clear cytoplasm, round nuclei, 
pleomorphism, atypia and few mitoses (fig. 1b) These morphologic features were consistent with those 
of a hidradenocarcinoma. Many of the glandular lumen demonstrated decapitation structures which 
indicate the release of part of the apocrine cell into the central part of the gland. The right inguinal 
lymph node was then radically resected with the capsule intact, measured 3.5 × 2.5 × 1.5 cm and 
exhibited homogenous, dull, tan tissue with punctate areas of hemorrhage (fig. 1c). The lymph node  
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tissue was nearly entirely replaced by tumor and was composed of similar epithelial cells with clear 
cytoplasm, ductal structures, infiltrative growth, atypia and mitoses. There was no evidence of 
geographic necrosis. 
Immunohistochemistry 
Tissue from the lymph node was then probed with antibodies directed against cytokeratins, the p53 
tumor suppressor family, the apoptotic regulator Bcl-2, the epidermal growth factor receptor (EGF-R) 
and the estrogen (ER), progesterone (PR) and Her2 receptors which define distinct breast cancer 
subtypes (Table 1). Tissue stained strongly for CK7, but was negative for CK20 consistent with a simple 
(glandular) epithelial origin. An antibody that recognized all known p53 isotypes (pan-53 antibody) 
yielded strong and diffuse nuclear staining in the majority of cells consistent with p53 overexpression 
(fig. 2a). Similarly, when probed with a pan-p63 antibody, a majority of cells also demonstrated strong 
nuclear reactivity and, importantly, these immunoreactive cells were seen throughout the tumor (fig. 
2b). Normally, p63 is expressed in the progenitor cell layers of certain tissues, e.g., skin, breast and 
prostate [3, 4], but these basal cells lose p63 expression as the cells withdraw from the stem cell 
compartment [5]. In transfected human keratinocytes, in vitro studies have demonstrated that p63 
triggers differentiation and is then down-regulated in terminally differentiated cells [3–5]. Moreover, 
p63 isoforms were then shown to function collectively as the molecular switch which regulates the 
developmental program of stratified epithelia [5]. A monoclonal antibody directed against the third 
member of the p53 family, p73, also demonstrated extensive, nuclear reactivity in the majority of cells in 
contrast to that seen in normal tissue (fig. 2c). 
A role for p63 in tumorigenesis has been implied by genomic amplification as well as overexpression 
in primary squamous cell tumors of the head and neck, lung, bladder, salivary gland and a subset of 
breast tumors [7–10]. The p63 gene contains 2 separate promoters which express at least 6 major 
transcripts that lead to 2 fundamentally different classes of proteins [2] (fig. 3). Three of the p63 
isoforms (TAp63α, β and γ) encode proteins with roles similar to p53, i.e., transactivation and induction 
of apoptosis, whereas the other 3 isoforms (ΔNp63α, β and γ) lack the acidic amino-terminal 
transactivation domain and may exert inhibitory effects on p53 activity. The ΔNp63 forms may function 
in a dominant negative manner to inhibit p53 by impairing tetramerization, blocking DNA binding or 
by physically binding to their gene products to inhibit functional activity. Aberrant ΔNp63 expression 
may preclude apoptosis-inducing activity and maintain the proliferative capacity of basal/progenitor 
cells. Interest in p63 stems from this ‘two genes in one’-concept, where differential transcription of a 
single gene yields products with either agonist or antagonist
 roles involved in neoplastic transformation. 
Importantly, the nuclear presence of ΔNp63 was detected widespread throughout the tumor (fig. 2d). 
Finally, weak staining was detected using an anti-EGF-R antibody, while no labeling was seen with 
antibodies directed against Bcl-2 or S-100 and, importantly, a lack of ER, PR and Her-2 staining was 
demonstrated which paralleled the subset of triple-negative breast cancers (data not shown). 
Molecular Pathogenesis 
To our knowledge, this is the first case report of a sweat gland tumor that displayed expression of 
both ΔNp63 and p73 and in addition demonstrated a triple-negative receptor status. A case of 
metastatic hidradenocarcinoma with ER
+/Her-2
+ status by IHC was reported and suggested a 
responsiveness to tamoxifen or trastuzumab [11]. In addition, a tenuous connection has been reported 
between Her-2 positivity and adnexal neoplasms [12]. Therefore, we explored the association between 
these breast tumor markers and adnexal neoplasms in order to elucidate the pathologic events 
responsible for tumorigenesis and to identify targeted forms of therapy. Global gene expression 
profiling uncovered previously unrecognized subsets of human breast cancer that include the triple-
negative tumors characterized by the lack of ER and PR expression, the absence of Her2 amplification, 
and the expression of basal epithelial markers [13]. Triple-negative breast cancers are the most common 
subtype arising in patients that harbor BRCA1 germline mutations. Recently, it was demonstrated that 
the ΔNp63 and TAp73 isoforms were coexpressed exclusively within certain triple-negative primary 
breast cancers that commonly exhibited p53 mutational inactivation. Consequently, inhibition of p63 
expression by RNA interference led to TAp73-dependent induction of Bcl-2 family members and 
subsequent apoptosis. Furthermore, breast cancer cells expressing ΔNp63α and TAp73 exhibited 
sensitivity to cisplatin, but not to other chemotherapeutic agents. Clearly, in tumors as rare as 
hidradenocarcinomas gene expression profiling is less feasible. However, by immunohistochemical 
methods, we have demonstrated the overexpression of p53, p63 and p73, the lack of ER and PR 
expression and the absence of Her2 amplification. Overexpression of the p53 protein predicts a mutated  
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gene status in this tumor type with a resultant effect on stability and functionality. In addition, we 
demonstrate the overexpression of ΔNp63 and expand the spectrum of tumors previously identified to 
exhibit deregulation of the p63/p73 pathway to include sweat gland tumors. 
Treatment and Management 
Currently, treatment options for sweat gland carcinomas are limited and surgical excision, with wide 
resection margins and regional lymph node dissection, is the only known curative therapy for patients 
with localized disease and, thus, was used as the primary treatment of this patient. Established 
guidelines that demonstrate a survival benefit for adjuvant chemotherapy in patients with newly 
diagnosed or recurrent disease are lacking, in part owing to the rarity of the disease and because large, 
randomized trials have not been performed. Similarly, the efficiency of adjuvant chemotherapy in 
combination with radiotherapy has not been demonstrated. Moreover, successful or transient response 
to various chemotherapy agents is limited to isolated case reports. Owing to the benefit of capecitabine 
in breast and colon cancer, a single hidradenocarcinoma patient was treated with this agent and 
demonstrated greater than 50% clinical remission with acceptable clinical and biological tolerance [14]. 
Such a promising objective response in a single patient suggests further study. Other case reports in 
patients with measurable disease included less successful treatment that used bleomycin with 
vincristine, vincristine with cyclophosphamide and vincristine combined with actinomycin D, VM-26, 
doxorubicin and dacarbazine [15]. The patient described in our report remains in complete remission 
12 months following diagnosis and excisional biopsy. In addition, the patient deferred on systemic 
chemotherapy in part because of the current lack of measurable disease. 
Conclusions 
The identification of novel cancer subtypes may facilitate more accurate diagnoses and 
promote the development of more specific, more effective and less toxic therapies for 
even rare tumors such as hidradenocarcinomas. Since a subset of breast tumors are triple 
negative and invoke the p63/p73 pathway with implications for cisplatin-based treatment, 
and since they are so rare and so little is known regarding the molecular events that are 
responsible for tumorigenesis, we explored the status of this tumor . By such an approach, 
we have identified a subtype of hidradenocarcinomas that harbor ΔNp63 and have 
uncovered an unforeseen commonality with the triple-negative breast tumors. Such a link 
between 2 seemingly disparate tumor types indicates a mutual pathway of tumorigenesis 
and suggests the potential for common therapeutic regimens. A role for the 
ΔNp63/TAp73 pathway may extend beyond primary breast cancers since ΔNp63α 
overexpression has been reported in numerous other squamous cell cancers [5–9]. Our 
findings support a role for ΔNp63 as a survival factor in certain metastatic adnexal skin 
cancers similar to its role in other solid tumors, and they provide a basis for treatment of 
metastatic disease with cisplatin-based regimens and indicate that these molecular 
markers may serve as a useful clinical predictor of cisplatin-sensitivity in treatment-
refractory tumors. Finally, the further development of molecular signatures remains of 
paramount importance to further unravel the biology specific to individual tumor 
subtypes and to guide the early clinical development of solid tumor treatment strategies. 
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Table 1. Immunohistochemical profile of metastatic hidradenocarcinoma tissue 
Molecular marker  Staining  Subcellular 
localization 
01. CK7  positive  cytoplasmic 
02. CK20  negative  – 
03. p53  positive  nuclear 
04. p63  strongly  positive  nuclear 
05. p73  positive  nuclear 
06. ΔNp63  strongly  positive  nuclear 
07.  EGF-R  very weakly positive  cell membrane 
08. Bcl-2  negative  – 
09. S-100  negative  – 
10. ER  negative  – 
11. PR  negative  – 
12. Her-2  negative  – 
Antibodies used to stain the metastatic hidradenocarcinoma tissue were: CK7 (Dako M7018), CK20 
(Dako M7019), p53 (Ventana D0–7), p63 (Dako M7247), p73 (Zymed 32–4200), ΔNp63 (Biolegend 
619001), Bcl-2 (Dako N1587), S-100 (Dako Z-0311), EGF-R (Dako M7298), ER (Dako M7047), PR 
(M3569) and Her2 (Dako K5204). 
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Fig. 1. a Hematoxylin-eosin staining of skin tumor tissue with gland formation, hyaline deposition and 
irregular, deep penetration (original magnification ×20). b High power hematoxylin-eosin view of the 
tumor with nuclear polymorphism, mitoses, and gland formation (original magnification ×200). 
c Hematoxylin-eosin of lymph node tissue with nearly complete replacement of the normal lymph 
node with tumor (original magnification ×20). 
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Fig. 2. Lymph node tumor stained with either a a pan-p53 monoclonal antibody (original magnification 
×200), b a p63 monoclonal antibody (original magnification ×200), c a p73 monoclonal antibody 
(original magnification ×200), or d a ΔNp63 monoclonal antibody (original magnification ×200). 
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Fig. 3. Schematic of the TA and ΔNp63 exon structures and gene products as predicted in the ‘two 
genes in one’-model. TA = Transactivation domain; ΔN = delta N domain; PR = proline-rich domain; 
DNB = DNA-binding domain; OD = oligomerization domain; SAM = sterile α-motif. 
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